Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
Genetron Holdings Limited (NASDAQ: GTH) announced it will release its unaudited financial results for Q1 ended March 31, 2022, on June 2, 2022, prior to U.S. market open. Management will host an investor conference call at 8:30 a.m. ET the same day. Genetron Health is recognized as a leading precision oncology platform in China, focusing on molecular profiling tests and early cancer screening products. The company continues to innovate in the field of cancer management by partnering with global biopharmaceutical companies.
- None.
- None.
BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open.
Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers:
| United States: | +1-833-239-5565 |
| China Domestic: | 400-820-5286 |
| Hong Kong: | +852-3018-6771 |
| International: | +65-6713-5590 |
| Conference ID: | 2889133 |
Participants are encouraged to dial into the call at least 15 minutes in advance due to high call volumes.
A simultaneous webcast of the conference call will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.genetronhealth.com.
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products. For more information, please visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.
Investor Relations Contact
US:
Hoki Luk
Head of Investor Relations
Email: hluk@genetronhealth.us
Phone: +1 (408) 891-9255
Philip Trip Taylor
Principle | Gilmartin Group
ir@genetronhealth.com
FAQ
When will Genetron Holdings report its Q1 2022 financial results?
What time is the conference call for Genetron Holdings' Q1 results?
How can I access the Genetron Holdings Q1 2022 earnings call?
What is Genetron Holdings' stock symbol?
